Regulus Therapeutics (NASDAQ:RGLS) Stock Price Crosses Above Two Hundred Day Moving Average – Here’s What Happened

Regulus Therapeutics Inc. (NASDAQ:RGLS)’s share price passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $1.46 and traded as high as $1.95. Regulus Therapeutics shares last traded at $1.80, with a volume of 779,048 shares trading hands.

Analysts Set New Price Targets

Several research firms have recently commented on RGLS. Canaccord Genuity Group reaffirmed a “buy” rating and set a $28.00 price target on shares of Regulus Therapeutics in a research report on Monday, March 17th. HC Wainwright reissued a “buy” rating and set a $10.00 price objective on shares of Regulus Therapeutics in a research report on Friday, March 14th. Finally, Wells Fargo & Company raised shares of Regulus Therapeutics from an “equal weight” rating to an “overweight” rating and upped their target price for the company from $3.00 to $6.00 in a research report on Thursday, March 27th. One investment analyst has rated the stock with a sell rating and four have issued a buy rating to the company’s stock. According to MarketBeat, Regulus Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $12.75.

Regulus Therapeutics Trading Down 6.4 %

The company has a fifty day moving average of $1.34 and a 200-day moving average of $1.46. The stock has a market cap of $111.62 million, a PE ratio of -1.57 and a beta of 1.42.

Regulus Therapeutics (NASDAQ:RGLS) last released its earnings results on Thursday, March 20th. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, meeting the consensus estimate of ($0.20). During the same period last year, the company earned ($0.40) earnings per share. As a group, research analysts anticipate that Regulus Therapeutics Inc. will post -0.88 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CEO Joseph P. Hagan acquired 50,000 shares of the business’s stock in a transaction dated Thursday, January 30th. The shares were acquired at an average price of $1.09 per share, with a total value of $54,500.00. Following the completion of the transaction, the chief executive officer now owns 260,808 shares of the company’s stock, valued at $284,280.72. The trade was a 23.72 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO Crispina Calsada sold 38,716 shares of Regulus Therapeutics stock in a transaction on Monday, January 13th. The shares were sold at an average price of $1.26, for a total value of $48,782.16. Following the completion of the transaction, the chief financial officer now owns 50,566 shares of the company’s stock, valued at approximately $63,713.16. This trade represents a 43.36 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 223,998 shares of company stock worth $282,237 in the last ninety days. 4.35% of the stock is owned by corporate insiders.

Institutional Trading of Regulus Therapeutics

Several hedge funds have recently added to or reduced their stakes in the company. Jane Street Group LLC purchased a new stake in shares of Regulus Therapeutics in the 3rd quarter valued at approximately $46,000. PEAK6 LLC acquired a new position in shares of Regulus Therapeutics during the fourth quarter worth $95,000. Velan Capital Investment Management LP purchased a new position in Regulus Therapeutics in the fourth quarter valued at $111,000. JPMorgan Chase & Co. raised its stake in Regulus Therapeutics by 193.4% in the third quarter. JPMorgan Chase & Co. now owns 78,972 shares of the biopharmaceutical company’s stock valued at $124,000 after buying an additional 52,059 shares in the last quarter. Finally, Barclays PLC lifted its holdings in Regulus Therapeutics by 285.2% during the 3rd quarter. Barclays PLC now owns 84,477 shares of the biopharmaceutical company’s stock worth $132,000 after buying an additional 62,549 shares during the last quarter. Institutional investors and hedge funds own 92.38% of the company’s stock.

About Regulus Therapeutics

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.